BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dietz J, Di Maio VC, de Salazar A, Merino D, Vermehren J, Paolucci S, Kremer AE, Lara M, Pardo MR, Zoller H, Degasperi E, Peiffer KH, Sighinolfi L, Téllez F, Graf C, Ghisetti V, Schreiber J, Fernández-Fuertes E, Boglione L, Muñoz-Medina L, Stauber R, Gennari W, Figueruela B, Santos J, Lampertico P, Zeuzem S, Ceccherini-Silberstein F, García F, Sarrazin C; HCV Virology Italian Resistance Network (VIRONET-C) collaborators., Spanish GEHEP-004 Collaborators., Members of the German HCV resistance study group. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. J Hepatol 2021;74:801-10. [PMID: 33220331 DOI: 10.1016/j.jhep.2020.11.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Martin MT, Patel S, Kulik L, Chan C. Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings. Journal of Hepatology 2021;75:251-4. [DOI: 10.1016/j.jhep.2021.02.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Soni S, Singh D, Aggarwal R, Veerapu NS. Enhanced fitness of hepatitis C virus increases resistance to direct-acting antivirals. J Gen Virol 2022;103. [PMID: 35133954 DOI: 10.1099/jgv.0.001699] [Reference Citation Analysis]
3 Ridruejo E, Pereson MJ, Flichman DM, Di Lello FA. Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions. World J Hepatol 2021; 13(9): 1069-1078 [PMID: 34630875 DOI: 10.4254/wjh.v13.i9.1069] [Reference Citation Analysis]
4 Pisano MB, Giadans CG, Flichman DM, Ré VE, Preciado MV, Valva P. Viral hepatitis update: Progress and perspectives . World J Gastroenterol 2021; 27(26): 4018-4044 [PMID: 34326611 DOI: 10.3748/wjg.v27.i26.4018] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zahid H, Aslam K, Dahl EH, Abbassi W, Adan S, Van den Bergh R, Balinska MA, Luck NH. DAA treatment failures in a low-resource setting with a high burden of hepatitis C infections: a case series. Oxf Med Case Reports 2022;2022:omac049. [PMID: 35619685 DOI: 10.1093/omcr/omac049] [Reference Citation Analysis]
6 Onorato L, Pisaturo M, Starace M, Minichini C, Di Fraia A, Astorri R, Coppola N. Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review. Viruses 2021;13:432. [PMID: 33800289 DOI: 10.3390/v13030432] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Huang SC, Kao JH. Strategies for hepatitis C virus treatment failure. J Formos Med Assoc 2021:S0929-6646(21)00426-5. [PMID: 34538553 DOI: 10.1016/j.jfma.2021.09.004] [Reference Citation Analysis]
8 Smith DA, Bradshaw D, Mbisa JL, Manso CF, Bibby DF, Singer JB, Thomson EC, da Silva Filipe A, Aranday-Cortes E, Ansari MA, Brown A, Hudson E, Benselin J, Healy B, Troke P, McLauchlan J, Barnes E, Irving WL. Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy. J Viral Hepat 2021;28:1256-64. [PMID: 34003556 DOI: 10.1111/jvh.13549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Malandris K, Kalopitas G, Theocharidou E, Germanidis G. The Role of RASs /RVs in the Current Management of HCV. Viruses 2021;13:2096. [PMID: 34696525 DOI: 10.3390/v13102096] [Reference Citation Analysis]
10 Sarrazin C. Treatment failure with DAA therapy: Importance of resistance. Journal of Hepatology 2021;74:1472-82. [DOI: 10.1016/j.jhep.2021.03.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
11 Manns MP, Maasoumy B. Breakthroughs in hepatitis C research: from discovery to cure. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35595834 DOI: 10.1038/s41575-022-00608-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Meszaros M, Truchi R, Ouzan D, Tran A, Bourlière M, Pageaux GP. Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients. Hepatology 2021;74:2304-6. [PMID: 34008214 DOI: 10.1002/hep.31909] [Reference Citation Analysis]
13 Dietz J, Sarrazin C. Reply to: "Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings". J Hepatol 2021;75:254-5. [PMID: 33892009 DOI: 10.1016/j.jhep.2021.04.017] [Reference Citation Analysis]
14 Bota S, Razpotnik M, Hucke F, Urak C, Flatscher K, Peck-Radosavljevic M. Challenges in hepatitis C elimination despite highly effective antiviral agents in patients with and without intravenous drug use. Wien Klin Wochenschr 2021;133:641-6. [PMID: 34032930 DOI: 10.1007/s00508-021-01868-1] [Reference Citation Analysis]